These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32295685)

  • 21. Short-term vs long-term dual antiplatelet therapy after drug-eluting stent implantation in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Int J Clin Pract; 2021 Jul; 75(7):e13938. PubMed ID: 33341109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of short-term dual antiplatelet therapy (≤6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Misumida N; Abo-Aly M; Kim SM; Ogunbayo GO; Abdel-Latif A; Ziada KM
    Clin Cardiol; 2018 Nov; 41(11):1455-1462. PubMed ID: 30225978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis.
    Basaraba JE; Barry AR
    J Cardiol; 2017 Jan; 69(1):353-358. PubMed ID: 27590413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short Duration vs Standard Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents - A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials.
    Wassef AW; Khafaji H; Syed I; Yan AT; Udell JA; Goodman SG; Cheema AN; Bagai A
    J Invasive Cardiol; 2016 Dec; 28(12):E203-E210. PubMed ID: 27630146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.
    Wang W; Liu J; Fang J; Liu Y; An T; Zou M; Cheng G
    Int J Cardiol; 2017 May; 235():73-86. PubMed ID: 28284499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P2Y
    Jin Y; Huang H; Shu X; Chen S; Lu L; Gao X; Wu Z
    Thromb Res; 2021 Feb; 198():115-121. PubMed ID: 33316640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials.
    Kheiri B; Simpson TF; Osman M; Golwala H; Radaideh Q; Kumar K; Rahmouni H; Divanji P; Cigarroa JE; Zahr F
    J Thromb Thrombolysis; 2020 Nov; 50(4):867-873. PubMed ID: 32607653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P2Y12 Inhibitor Monotherapy After Short-Term Dual Antiplatelet Therapy in Acute Coronary Syndrome.
    Singh S; Garg A; Tantry US; Bliden K; Abbott JD; Gurbel PA
    Am J Cardiol; 2024 Aug; 224():1-8. PubMed ID: 38734399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y
    Lahu S; Bristot P; Gewalt S; Goedel A; Giacoppo D; Schüpke S; Schunkert H; Kastrati A; Sarafoff N
    J Atheroscler Thromb; 2022 Jul; 29(7):1001-1019. PubMed ID: 34248087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bleeding versus thrombosis: role of short DAPT in complex lesions.
    Calcagno S; Lucisano L; Mancone M; Cavallo E; Pennacchi M; Stio RE; Sardella G
    Minerva Cardioangiol; 2015 Dec; 63(6):533-46. PubMed ID: 26334115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintained P2Y
    Fan ZG; Tian NL; He SH; Ma GS
    J Clin Pharm Ther; 2022 Jul; 47(7):860-869. PubMed ID: 35218029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
    Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients.
    Bianco M; Careggio A; Destefanis P; Luciano A; Perrelli MG; Quadri G; Rossini R; Campo G; Vizzari G; D'Ascenzo F; Anselmino M; Biondi-Zoccai G; Ibáñez B; Montagna L; Varbella F; Cerrato E
    Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):196-205. PubMed ID: 32544220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of Dual Antiplatelet Therapy and Late Stent Thrombosis Following Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Simple Meta-Analysis of Randomized Controlled Trials.
    Lin BY; Li P; Wu P; Jiang RN; Bundhun PK; Ahmed MA
    Adv Ther; 2019 Nov; 36(11):3166-3173. PubMed ID: 31535329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.
    Abo-Salem E; Alsidawi S; Jamali H; Effat M; Helmy T
    Cardiovasc Ther; 2015 Oct; 33(5):253-63. PubMed ID: 26010419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.
    Kuno T; Ueyama H; Takagi H; Bangalore S
    Am Heart J; 2020 Sep; 227():82-90. PubMed ID: 32693196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis.
    Xu Y; Shen Y; Chen D; Zhao P; Jiang J
    J Interv Cardiol; 2021; 2021():9934535. PubMed ID: 34035674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
    Choi KH; Park YH; Song YB; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Oh JH; Chun WJ; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Gwon HC; Hahn JY;
    JAMA Cardiol; 2022 Nov; 7(11):1100-1108. PubMed ID: 36169938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.